albuterol/fluticasone (TEV-'248) / Teva - LARVOL DELTA

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations (clinicaltrials.gov) - P3 | N=2772 | Active, not recruiting | Sponsor: Teva Branded Pharmaceutical Products R&D LLC | Recruiting ➔ Active, not recruiting

Enrollment closed • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations (clinicaltrials.gov) - P3 | N=1000 | Recruiting | Sponsor: Teva Branded Pharmaceutical Products R&D LLC | N=764 ➔ 1000

Enrollment change • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations (clinicaltrials.gov) - P3 | N=2700 | Recruiting | Sponsor: Teva Branded Pharmaceutical Products R&D LLC | Active, not recruiting ➔ Recruiting

Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations (clinicaltrials.gov) - P3 | N=2700 | Active, not recruiting | Sponsor: Teva Branded Pharmaceutical Products R&D LLC | Recruiting ➔ Active, not recruiting

Enrollment closed • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations (clinicaltrials.gov) - P3 | N=2700 | Recruiting | Sponsor: Teva Branded Pharmaceutical Products R&D LLC | Trial completion date: Jul 2026 ➔ Oct 2026 | Trial primary completion date: Jul 2026 ➔ Oct 2026

Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations (clinicaltrials.gov) - P3 | N=2196 | Recruiting | Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Active, not recruiting ➔ Recruiting

Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations (clinicaltrials.gov) - P3 | N=2196 | Active, not recruiting | Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Recruiting ➔ Completed | N=22 ➔ 30

Enrollment change • Trial completion • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old (clinicaltrials.gov) - P1 | N=22 | Recruiting | Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old (clinicaltrials.gov) - P1 | N=22 | Not yet recruiting | Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

New P1 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations (clinicaltrials.gov) - P3 | N=2196 | Recruiting | Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

New P3 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases